Page 57 - 2021_07-Haematologica-web

Synergistic targeting of WEE1 and GLS1 in T-ALL
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combina- tion with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). J Clin Oncol. 2016;34(Suppl 15):1011-1011.
40.Girardi T, Vicente C, Cools J, De Keersmaecker K. The genetics and molecu- lar biology of T-ALL. Blood. 2017;129(9): 1113-1123.
41. Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM, Porter CC. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget. 2015;6(29):28001-28010.
42. Garcia TB, Snedeker JC, Baturin D, et al. A small-molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Mol Cancer Ther. 2017; 16(10):2058-2068.
43. Gao P, Tchernyshyov I, Chang TC, et al. c- Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009; 458(7239):762-765.
44. Qie S, Yoshida A, Parnham S, et al. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human
esophageal squamous cell carcinoma. Nat
Commun. 2019;10(1):1296.
45.Leijen S, van Geel RM, Pavlick AC, et al.
46.
Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combina- tion with gemcitabine, cisplatin, or carbo- platin in patients with advanced solid tumors. J Clin Oncol. 2016;34(36):4371- 4380.
Do K, Wilsker D, Ji J, et al. Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol. 2015;33(30): 3409-3415.
haematologica | 2021; 106(7)
1827